基于依地酸二钠的螯合疗法用于既往心肌梗死合并糖尿病患者:TACT2随机临床试验
TACT2是一项在美国和加拿大88个中心开展的双盲、安慰剂对照、2×2析因试验,纳入959例50岁以上、既往心肌梗死且合并糖尿病的患者,比较40次每周静脉输注依地酸二钠(EDTA)螯合液与安慰剂对心血管复合终点的影响。结果显示,螯合组与安慰剂组主要终点事件发生率无显著差异(35.6% vs 35.7%,校正HR 0.93,95%CI 0.76-1.16,P=0.53),尽管螯合有效降低了血铅水平。
要点
- 在既往心肌梗死合并糖尿病患者中,EDTA螯合未显著降低主要心血管复合终点事件风险(校正HR 0.93,95%CI 0.76-1.16,P=0.53)。
- 螯合组5年主要事件累积发生率为45.8%,安慰剂组为46.5%。
- 螯合将血铅中位数从基线9.03 μg/L降至第40次输注时的3.46 μg/L(P<0.001)。
核心结论
- 尽管EDTA螯合有效降低了血铅水平,但在合并糖尿病且有心肌梗死史的稳定性冠心病患者中,未能有效减少心血管事件。
研究设计与样本
- 2×2析因、双盲、安慰剂对照、多中心试验,在美国和加拿大88个中心开展,纳入50岁以上、既往心肌梗死至少6周且合并糖尿病的患者。
- 共有959例参与者(中位年龄67岁,IQR 60-72岁;女性27%;白人78%,黑人10%,西班牙裔20%),其中483例至少接受1次螯合输注,476例至少接受1次安慰剂输注。
- 参与者随机接受40次每周静脉输注EDTA螯合液或匹配安慰剂,并随机接受每日两次口服高剂量多种维生素和矿物质补充剂或匹配安慰剂,持续60个月;本文报告螯合与安慰剂输注的比较。
- 中位随访48个月;主要比较基于至少接受1次分配输注的患者。
主要发现
- 主要终点事件(全因死亡、心肌梗死、卒中、冠状动脉血运重建或不稳定型心绞痛住院的复合终点)在螯合组发生172例(35.6%),安慰剂组发生170例(35.7%)(校正HR 0.93,95%CI 0.76-1.16,P=0.53)。
- 5年主要事件累积发生率螯合组为45.8%,安慰剂组为46.5%。
- 心血管死亡、心肌梗死或卒中事件在螯合组发生89例(18.4%),安慰剂组发生94例(19.7%)(校正HR 0.89,95%CI 0.66-1.19)。
- 全因死亡在螯合组发生84例(17.4%),安慰剂组发生84例(17.6%)(校正HR 0.96,95%CI 0.71-1.30)。
- 螯合组血铅中位数从基线9.03 μg/L降至第40次输注时的3.46 μg/L(P<0.001);安慰剂组相应水平分别为9.3 μg/L和8.7 μg/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In 2013, the Trial to Assess Chelation Therapy (TACT) reported that edetate disodium (EDTA)-based chelation significantly reduced cardiovascular disease (CVD) events by 18% in 1708 patients with a prior myocardial infarction (MI). OBJECTIVE: To replicate the finding of TACT in individuals with diabetes and previous MI. DESIGN, SETTING, AND PARTICIPANTS: A 2 × 2 factorial, double-masked, placebo-controlled, multicenter trial at 88 sites in the US and Canada, involving participants who were 50 years or older, had diabetes, and had experienced an MI at least 6 weeks before recruitment compared the effect of EDTA-based chelation vs placebo infusions on CVD events and compared the effect of high doses of oral multivitamins and minerals with oral placebo. This article reports on the chelation vs placebo infusion comparisons. INTERVENTIONS: Eligible participants were randomly assigned to 40 weekly infusions of an EDTA-based chelation solution or matching placebo and to twice daily oral, high-dose multivitamin and mineral supplements or matching placebo for 60 months. This article addresses the chelation study. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. Median follow-up was 48 months. Primary comparisons were made from patients who received at least 1 assigned infusion. RESULTS: Of the 959 participants (median age, 67 years [IQR, 60-72 years]; 27% females; 78% White, 10% Black, and 20% Hispanic), 483 received at least 1 chelation infusion and 476 at least 1 placebo infusion. A primary end point event occurred in 172 participants (35.6%) in the chelation group and in 170 (35.7%) in the placebo group (adjusted hazard ratio [HR], 0.93; 95% CI, 0.76-1.16; P = .53). The 5-year primary event cumulative incidence rates were 45.8% for the chelation group and 46.5% for the placebo group. CV death, MI, or stroke events occurred in 89 participants (18.4%) in the chelation group and in 94 (19.7%) in the placebo group (adjusted HR, 0.89; 95% CI, 0.66-1.19). Death from any cause occurred in 84 participants (17.4%) in the chelation group and in 84 (17.6%) in the placebo group (adjusted HR, 0.96; 95% CI, 0.71-1.30). Chelation reduced median blood lead levels from 9.03 μg/L at baseline to 3.46 μg/L at infusion 40 (P < .001). Corresponding levels in the placebo group were 9.3 μg/L and 8.7 μg/L, respectively. CONCLUSIONS AND RELEVANCE: Despite effectively reducing blood lead levels, EDTA chelation was not effective in reducing cardiovascular events in stable patients with coronary artery disease who have diabetes and a history of MI. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02733185.
引用
- Lamas GA, Anstrom KJ, Navas-Acien A, et al. Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial. JAMA. 2024. PMID: 39141382. doi:10.1001/jama.2024.11463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。